Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Explains How It Will Resume Inspections Suspended By Pandemic

Executive Summary

Phased approach will prioritize the safety of FDA and industry employees while striking an appropriate balance between a scaled-back surveillance inspection program and the continuation of providing robust regulatory oversight,’ Commissioner Hahn says in a memo from self-isolation.

You may also be interested in...



What The FDA’s Inspections Q&A Guidance Really Means: It’s Time To Offer Virtual Inspections

Compliance experts see possibilities in offering video tours as the FDA offers “holistic” approach to assessing sites during pandemic.

Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19

Coronavirus Notebook: Emergency Use Authorization For Blood Plasma Therapy, Pandemic Workloads, US FDA Offices, Rx Mail Deliveries

US FDA issues controversial use emergency authorization for blood plasma therapy while agency officials note workloads nearly double under coronavirus treatment acceleration program. This and more in the Pink Sheet's latest coronavirus update.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel